UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular...

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Stereotactic ablative radiotherapy (SABR) utilization has significantly increased in the UK over the last decade.
• This expansion is attributed to UK clinical trials and the NHS England Commissioning through Evaluation program.
• A prior consensus on normal tissue constraints for SABR was established in 2017 based on available literature.

Purpose of the Study:

• To review and update the 2017 UK SABR Consortium consensus on normal tissue constraints.
• To address the growing body of literature and the development of new SABR services in the UK.
• To provide a resource for facilitating safe and consistent SABR practice.

Main Methods:

• Literature review of published studies on SABR over the past five years.
• Analysis of current UK clinical trial data and commissioning programs.
• Consensus development by the UK SABR Consortium.

Main Results:

• The volume of published literature on SABR has substantially increased since 2017.
• Multiple UK centers are actively developing and expanding SABR services.
• An updated consensus on normal tissue constraints is necessary due to advancements and increased use.

Conclusions:

• An updated consensus on normal tissue constraints for SABR is timely and necessary.
• This revised guidance will support the safe and consistent implementation of SABR across the UK.
• The document aims to serve as a valuable resource for healthcare professionals involved in SABR.